Lupin launches generic Trilipix delayed release capsules in US

Lupin, a Rs.9,450 crore plus fourth largest Indian pharma company, has launched generic Trilipx delayed-release capsules 45 mg & 135 mg in US through its subsidiary Lupin Pharmaceuticals, Inc.

Lupin's fenofibric acid delayed-release capsules 45 mg and 135 mg are the generic equivalent of AbbVie Inc's Trilipix delayed release capsule 45 mg and 135 mg strengths are indicated as co-administration therapy with statins for the treatment of mixed dyslipidemia, treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.

Trilipix delayed-release capsules had annual sales of approximately US$ 449.5 million.